Up next

Autoplay

Ubrelvy

0 Views • 08/28/25
Share
Side Effects
Side Effects
Subscribers
0

Approved in December 2019, Ubrelvy represents the first drug in the gepants family. This orally administered small molecule blocks the CGRP receptor thought to be central to generation of migraine headache pain. It treats the acute migraine rather than acting to prevent future attacks.

Early administration within 4 hours of headache onset provides more advantages than delayed treatment. A repeat dose of Ubrelvy after 2 hours may offer additional improvement if initial treatment fails to markedly reduce the symptoms.

Advertising claims Ubrelvy leads to freedom from pain within 2 hours. Unfortunately studies sponsored by the drug company reveal this only occurs in about 20% of individuals receiving the drug as compared to about 10% of those in the placebo group.

About 15% of the Ubrelvy group obtained sustained freedom from migraine headache pain from 2 to 24 hours after treatment as contrasted to about 9% among those treated with an inactive placebo.

Ubrelvy has not been compared to any of the standard medicines prescribed for acute migraine headache.

Show more
0 Comments sort Sort By

Up next

Autoplay